Evaluation and Treatment of Stem Cell Transplant-Related Dermatoses
详细信息    查看全文
  • 作者：Jonathan Cotliar
  • 关键词：Stem cell transplant ; Bone marrow transplant ; Hematopoietic stem cell transplant ; Graft ; versus ; host disease ; Toxic erythema of chemotherapy ; Viral exanthem ; Drug eruption ; Engraftment syndrome ; Eruption of lymphocyte recovery
  • 刊名：Current Dermatology Reports
  • 出版年：2016
  • 出版时间：March 2016
  • 年：2016
  • 卷：5
  • 期：1
  • 页码：42-48
  • 全文大小：577 KB
  • 参考文献：1.Horn TD, Redd JV, Karp JE, Beschorner WE, Burke PJ, Hood AF. Cutaneous eruptions of lymphocyte recovery. Arch Dermatol. 1989;125(11):1512–7.CrossRef PubMed
    2.Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.CrossRef PubMed
    3.Tabbara IA, Zimmerman K, Morgan C, Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med. 2002;162(14):1558–66.CrossRef PubMed
    4.Salmasian H, Rohanizadegan M, Banihosseini S, et al. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Cochrane Database Syst Rev. 2010;1:CD005565.PubMed
    5.Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100(12):3877–86.CrossRef PubMed
    6.••
Pasquini MCZX. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR summary slides. 2014. http://www.cibmtr.org/ . Data presented in these slides is the most current with respect to hematopoietic stem cell transplantation outcomes.
7.Pallua S, Giesinger J, Oberguggenberger A, et al. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant. 2010;45(10):1534–9.CrossRef PubMed
8.Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation. 1994;58(4):437–42.CrossRef PubMed
9.Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304.CrossRef PubMed
10.Mays SR, Kunishige JH, Truong E, Kontoyiannis DP, Hymes SR. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg. 2007;26(3):155–62.CrossRef PubMed
11.Sale GLK, Barker E, Shulman H, Thomas E. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol. 1977;89:621–36.PubMed PubMedCentral
12.Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol. 1997;21(9):988–96.CrossRef PubMed
13.Kuykendall TD, Smoller BR. Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation. J Am Acad Dermatol. 2003;49(6):1081–5.CrossRef PubMed
14.Quaglia A, Duarte R, Patch D, Ngianga-Bakwin K, Dhillon AP. Histopathology of graft versus host disease of the liver. Histopathology. 2007;50(6):727–38.CrossRef PubMed
15.Washington K, Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol. 2009;40(7):909–17.CrossRef PubMed
16.Firoz BF, Lee SJ, Nghiem P, Qureshi AA. Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol. 2006;142(2):175–82.CrossRef PubMed
17.Srinivasan R, Daniels J, Fusaro V, et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol. 2006;34(6):796–801.CrossRef PubMed
18.Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273–8.CrossRef PubMed PubMedCentral
19.Paczesny SBT, Levine JE, Hogan J, Crawford J, Coffing B, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra12.CrossRef
20.•
Bruggen MC, Petzelbauer P, Greinix H, et al. Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease. J Invest Dermatol. 2015;135(4):999–1006. Elafin has been purported to be a unique skin and serum biomarker that may help differentiate aGVHD from other dermatoses early after transplant. This paper further demonstrates that higher expression of skin elafin may portend a worse prognosis in aGVHD.
21.••
Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol. 2015;2(1):e21–9. A new biomarker panel that can reliably stratify aGVHD patients early in their posttransplant course, even prior to the maximum severity of clinical features has developed.
22.Cornejo CM, Kim EJ, Rosenbach M, Micheletti RG. Atypical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2015;72(4):690–5.CrossRef PubMed
23.Friedman KJ, LeBoit PE, Farmer ER. Acute follicular graft-vs-host reaction: a distinct clinicopathologic presentation. Arch Dermatol. 1988;124(5):688–91.CrossRef PubMed
24.Marra DE, McKee PH, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol. 2004;51(4):543–6.CrossRef PubMed
25.Massi D, Franchi A, Pimpinelli N, Laszlo D, Bosi A, Santucci M. A reappraisal of the histopathologic criteria for the diagnosis of cutaneous allogeneic acute graft-vs-host disease. Am J Clin Pathol. 1999;112(6):791–800.PubMed
26.McNeel D, Rubio MT, Damaj G, et al. Hypereosinophilia as a presenting sign of acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 2002;74(12):1797–800.CrossRef PubMed
27.Weaver J, Bergfeld WF. Quantitative analysis of eosinophils in acute graft-versus-host disease compared with drug hypersensitivity reactions. Am J Dermatopathol. 2010;32(1):31–4.CrossRef PubMed
28.Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65(4):726–32.CrossRef PubMed
29.••
Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplant. 2012;48(5):646–50. A wonderful review of toxic erythema of chemotherapy with important points about symptoms, morphology and anatomic distribution of its presentation.
30.Bauer DJ, Hood AF, Horn TD. Histologic comparison of autologous graft-vs-host reaction and cutaneous eruption of lymphocyte recovery. Arch Dermatol. 1993;129(7):855–8.CrossRef PubMed
31.Ginarte M, Peteiro C, Toribio J. Guess what! Eruption of lymphocyte recovery. Eur J Dermatol. 1999;9(4):323–4.PubMed
32.••Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50(4):469–75. A comprehensive review of the nuances between engraftment syndrome and aGVHD.
33.Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant. 1995;16(1):175–82.PubMed
34.Gorak E, Geller N, Srinivasan R, et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant. 2005;11(7):542–50.CrossRef PubMed
35.Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant. 1996;18(1):177–84.PubMed
36.Nurnberger W, Willers R, Burdach S, Gobel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol. 1997;74(5):221–4.CrossRef PubMed
37.Moreb JS, Kubilis PS, Mullins DL, Myers L, Youngblood M, Hutcheson C. Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients. Bone Marrow Transplant. 1997;19(2):101–6.CrossRef PubMed
38.Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant. 1992;10(1):1–14.PubMed
39.Rabinowitz J, Petros WP, Stuart AR, Peters WP. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood. 1993;81(9):2452–9.PubMed
40.Takatsuka H, Takemoto Y, Yamada S, et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant. 2000;26(4):419–26.CrossRef PubMed
41.Edenfield WJ, Moores LK, Goodwin G, Lee N. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant. 2000;25(4):405–9.CrossRef PubMed
42.•Jang KT, Song KY, Kim BK. Histological features and immune cell changes in skin lesions of engraftment syndrome of children undergoing hematopoietic stem cell transplantation. Histol Histopathol. 2012;27(2):235–40. Important paper that describes histologic features of engraftment syndrome and compare to those features in aGVHD.
43.Kitamura K, Asada H, Iida H, et al. Relationship among human herpesvirus 6 reactivation, serum interleukin 10 levels, and rash/graft-versus-host disease after allogeneic stem cell transplantation. J Am Acad Dermatol. 2008;58(5):802–9.CrossRef PubMed
44.•Dulery R, Salleron J, Dewilde A, et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant. 2012;18(7):1080–9. Demonstrates the relationship between HHV-6 reactivation and aGVHD onset.
45.Poutsiaka DD, Munson D, Price LL, Chan GW, Snydman DR. Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated. Bone Marrow Transplant. 2011;46(2):300–7.CrossRef PubMed PubMedCentral
46.Gammon B, Cotliar J. Viral infection as a trigger in flares of acute graft-versus-host disease. Br J Dermatol. 2013;168(4):906–8.CrossRef PubMed
47.Jaskula E, Dlubek D, Sedzimirska M, Duda D, Tarnowska A, Lange A. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. Transplant Proc. 2010;42(8):3273–6.CrossRef PubMed
  • 作者单位：Jonathan Cotliar (1)

    1. Division of Dermatology, City of Hope National Medical Center, 1500 East Duarte Road, MOB 2011A, Duarte, CA, 91010, USA
  • 刊物主题：Dermatology; Medicine/Public Health, general;
  • 出版者：Springer US
  • ISSN：2162-4933
    • 文摘
    Skin eruptions that develop early after hematopoietic stem cell transplantation are a unique group of dermatoses that are often clinically and histologically similar to one another, despite the variability in etiology. Current diagnostic criteria cannot reliably distinguish between acute graft-versus-host disease, eruption of lymphocyte recovery, engraftment syndrome, toxic erythema of chemotherapy, drug eruptions, and viral exanthema. Prospective trials that incorporate biomarker panels and participation by dermatology consultants in the evaluation of these patients hold promise as a method by which more accurate diagnosis of these dermatoses can be made.

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700